炎症性肠病在轴性脊椎关节炎中不会产生更高的疾病活性或更大的放射性进展
Patricia Remalante-Rayco1,2, Yassir Daghistani3, Tina Chim1
1Schroeder Arthritis Institute, Toronto Western Hospital, Spondylitis Program, University Health Network, Toronto, Ontario, Canada.
Rheumatology (Oxford, England)
|August 18, 2025
概括
轴性脊柱关节炎 (axSpA) 患者的炎症性肠病 (IBD) 没有恶化疾病活动或放射性进展. 这些发现表明共享机制,但没有IBD对axSpA的恶化.
科学领域:
- 类风湿病学 类风湿病学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 轴性脊椎关节炎 (axSpA) 和炎症性肠病 (IBD) 分享重叠的免疫病原性机制.
- 在axSpA患者中IBD的并发症很常见,需要对它们的相互作用进行调查.
研究的目的:
- 确定IBD的存在是否会影响axSpA.中的疾病活性.
- 评估IBD对axSpA患者放射性进展的影响.
主要方法:
- 一项纵向队列研究包括1451名axSpA患者,184人 (13%) 患有IBD.
- 疾病活动被评估使用浴性椎炎疾病活动指数 (BASDAI).
- 放射性进展是通过两年时间内的修改后的结脊髓炎得分 (mSASSS) 的变化来衡量.
主要成果:
- 患有axSpA和IBD的患者表现出明显的临床特征,包括较低的HLA-B27阳性度和较高的脑膜炎,外周关节炎和C-反应蛋白升高率.
- IBD与活性 axSpA (OR 0.98,95% CI 0.75-1.28) 的风险增加无关.
- 在IBD和放射性进展之间没有发现显著的关联 (OR 1.45,95% CI 0.78-2.73).
结论:
- 虽然axSpA-IBD患者具有独特的临床特征,但IBD似乎不会加剧axSpA疾病活动或放射性进展.
- 这些发现表明,尽管IBD具有共同的炎症路径,但IBD不会恶化axSpA结果.
- 需要进一步的研究来探索IBD严重程度和持续时间对长期axSpA预后的影响.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Inflammatory Bowel Disease I: Ulcerative Colitis
321
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
321
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236


